Allspring Global Investments Holdings LLC Has $266,000 Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Allspring Global Investments Holdings LLC decreased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 6.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,851 shares of the company’s stock after selling 433 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Janux Therapeutics were worth $266,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $29,000. Amalgamated Bank boosted its holdings in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new position in Janux Therapeutics in the second quarter worth approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Janux Therapeutics in the second quarter worth approximately $151,000. Finally, AQR Capital Management LLC bought a new position in Janux Therapeutics in the second quarter worth approximately $215,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 0.7 %

Shares of JANX opened at $54.39 on Monday. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -59.77 and a beta of 3.52. The stock has a 50 day moving average of $48.09 and a 200 day moving average of $46.14. Janux Therapeutics, Inc. has a 12 month low of $5.65 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. The company had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. Janux Therapeutics’s revenue was up 709.1% compared to the same quarter last year. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 420,610 shares of company stock valued at $19,288,666. 29.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JANX. UBS Group began coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank cut their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.